Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases

Inclusion Criteria: 1. Age ≥19 years at the time of informed consent. 2. Suspected or known shoulder joint diseases requiring MRA for diagnosis or evaluation at screening. 3. Voluntarily decided to participate in the study and provided written consent after receiving a sufficient explanation about this study and after fully understanding the information. Exclusion Criteria: 1. Subjects with contraindications to MRI 2. Subjects expected to be clinically unstable during the study 3. Subjects who have received or used another IP or investigational device within 4 weeks or ≥5 half-lives, whichever is longer, prior to informed consent. 4. Pregnant or breast-feeding women, or women of childbearing potential and men who do not agree to use appropriate methods of contraception during the study. 5. Determined to be ineligible to participate in the study by the investigator due to any other reasons.